04/28/2025
5:04 PM | Halozyme Therapeutics (Issuer)
Henderson Jeffrey William (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
04/28/2025
4:18 PM | BlackRock, Inc. (Filed by)
Halozyme Therapeutics (Subject)
| Form SCHEDULE 13G/A | |
04/01/2025
5:32 PM | Halozyme Therapeutics (Issuer)
Henderson Jeffrey William (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/18/2025
3:17 PM | Halozyme Therapeutics (Filer)
| Form ARS | |
03/18/2025
3:10 PM | Halozyme Therapeutics (Filer)
| Form DEF 14A | |
03/03/2025
7:46 PM | Halozyme Therapeutics (Issuer)
Henderson Jeffrey William (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/27/2025
5:32 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/25/2025
3:32 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
02/24/2025
4:07 PM | Halozyme Therapeutics (Issuer)
Snyder Mark Howard (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/24/2025
4:11 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/21/2025
5:49 PM | Halozyme Therapeutics (Issuer)
LaBrosse Nicole (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for HALO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter. |
02/21/2025
5:50 PM | Halozyme Therapeutics (Issuer)
Snyder Mark Howard (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/21/2025
5:52 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/21/2025
5:47 PM | Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/18/2025
5:37 PM | Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/18/2025
5:39 PM | Halozyme Therapeutics (Issuer)
LaBrosse Nicole (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/18/2025
5:41 PM | Halozyme Therapeutics (Issuer)
Snyder Mark Howard (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2025
5:12 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2025
5:08 PM | Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2025
5:09 PM | Halozyme Therapeutics (Issuer)
LaBrosse Nicole (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2025
5:11 PM | Halozyme Therapeutics (Issuer)
Snyder Mark Howard (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/04/2025
5:07 PM | Halozyme Therapeutics (Issuer)
Henderson Jeffrey William (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/03/2025
3:21 PM | Halozyme Therapeutics (Subject)
Henderson Jeffrey William (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
01/08/2025
7:00 AM | Halozyme Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/07/2025
3:14 PM | Halozyme Therapeutics (Issuer)
Henderson Jeffrey William (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/06/2025
4:12 PM | Halozyme Therapeutics (Issuer)
Snyder Mark Howard (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/06/2025
3:26 PM | Halozyme Therapeutics (Subject)
Henderson Jeffrey William (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
11/12/2024
8:36 AM | Artisan Partners Limited Partnership (Filed by)
Halozyme Therapeutics (Subject)
| Form SC 13G/A | |
10/31/2024
3:05 PM | Halozyme Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/17/2024
8:36 AM | Halozyme Therapeutics (Subject)
STATE STREET CORP (Filed by)
| Form SC 13G | |
10/16/2024
5:53 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/16/2024
3:14 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/15/2024
3:34 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/09/2024
4:39 PM | Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
10/09/2024
3:09 PM | Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
10/08/2024
3:08 PM | Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/26/2024
5:06 PM | Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/25/2024
3:00 PM | Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/24/2024
3:05 PM | Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/18/2024
5:49 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/18/2024
3:01 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
Here’s How to Claim Your Stake in Elon’s Private Company, xAI (Ad) I predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new millionaires than any tech advance in history.
And for a limited time, you have the chance to claim a stake in this project, even though it’s housed inside Elon’s private company, xAI. All the details are waiting for you now — but you need to act before the May 1st funding window clos |
09/12/2024
4:56 PM | Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/12/2024
3:12 PM | Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/11/2024
3:05 PM | Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
09/10/2024
3:16 PM | Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/27/2024
6:49 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/21/2024
5:03 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/20/2024
3:16 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/15/2024
3:59 PM | Halozyme Therapeutics (Issuer)
Torley Helen (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/15/2024
3:31 PM | Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/13/2024
3:19 PM | Halozyme Therapeutics (Subject)
Torley Helen (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
08/07/2024
3:41 PM | Halozyme Therapeutics (Subject)
Posard Matthew L. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/24/2024
4:48 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/24/2024
3:05 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/23/2024
3:11 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
07/22/2024
3:13 PM | Halozyme Therapeutics (Subject)
LaBrosse Nicole (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/28/2024
3:51 PM | Halozyme Therapeutics (Subject)
LaBrosse Nicole (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/27/2024
3:29 PM | Halozyme Therapeutics (Subject)
LaBrosse Nicole (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/26/2024
3:16 PM | Halozyme Therapeutics (Subject)
LaBrosse Nicole (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/20/2024
3:17 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/18/2024
3:22 PM | Halozyme Therapeutics (Subject)
LaBarre Michael J. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/14/2024
3:17 PM | Halozyme Therapeutics (Issuer)
Snyder Mark Howard (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/11/2024
3:40 PM | Halozyme Therapeutics (Subject)
Posard Matthew L. (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
05/22/2024
4:24 PM | Halozyme Therapeutics (Issuer)
LaBarre Michael J. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/07/2024
3:05 PM | Halozyme Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
Buy HALO Stock Free HALO Stock Alerts